WZ-4002

Details

Stereochemistry	ACHIRAL
Molecular Formula	C25H27ClN6O3
Molecular Weight	494.973
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC(=CC=C1NC2=NC=C(Cl)C(OC3=CC=CC(NC(=O)C=C)=C3)=N2)N4CCN(C)CC4

InChI

InChIKey=ITTRLTNMFYIYPA-UHFFFAOYSA-N

InChI=1S/C25H27ClN6O3/c1-4-23(33)28-17-6-5-7-19(14-17)35-24-20(26)16-27-25(30-24)29-21-9-8-18(15-22(21)34-3)32-12-10-31(2)11-13-32/h4-9,14-16H,1,10-13H2,2-3H3,(H,28,33)(H,27,29,30)

HIDE SMILES / InChI

Molecular Formula	C25H27ClN6O3
Molecular Weight	494.973
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20033049

WZ4002 is a covalent pyrimidine inhibitor of EGFR, it demostrated the potency and relative selectivity for mutant EGFR forms. WZ4002 suppresses the growth of EGFR containing cell lines. It was effective in murine models of lung cancer driven by mutant EGFR.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Epidermal growth factor receptor erbB1 62 Target ID: CHEMBL203 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20033049	Inhibitor 8504		2.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Lung cancer 70 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20033049 https://www.ncbi.nlm.nih.gov/pubmed/24386407	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation.	2016-10-25	27626175
Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.	2015-09	26036643
Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors.	2013	24386407
Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.	2012-10	22844075
Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.	2012-07-01	22553343
WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors.	2012-03	22157722
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.	2009-12-24	20033049

Patents

Sample Use Guides

In Vivo Use Guide

mouse lung cancer models : WZ4002 at 25mg/kg gavage daily

Route of Administration: Oral

In Vitro Use Guide

WZ4002 suppresses the growth of mutant EGFR T790M containing cell lines (IC50 values are in nanomolar range) and inhibit EGFR phosphorylation (0.1-1 uM)

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:37:03 GMT 2025` Edited by `admin` on `Mon Mar 31 21:37:03 GMT 2025`
Record UNII	6BQ432Z61M
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

WZ4002

Preferred Name

English

WZ-4002

Common Name

English

N-(3-((5-CHLORO-2-((2-METHOXY-4-(4-METHYL-1-PIPERAZINYL)PHENYL)AMINO)-4-PYRIMIDINYL)OXY)PHENYL)-2-PROPENAMIDE

Systematic Name

English

2-PROPENAMIDE, N-(3-((5-CHLORO-2-((2-METHOXY-4-(4-METHYL-1-PIPERAZINYL)PHENYL)AMINO)-4-PYRIMIDINYL)OXY)PHENYL)-

Systematic Name

English

Code System Code Type Description

CAS

1213269-23-8